Barbara Klencke - 14 Mar 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Chief Medical Officer
Signature
/s/ Mary Christina Thomson, Attorney-In-Fact for Barbara Klencke
Issuer symbol
SRRA
Transactions as of
14 Mar 2022
Transactions value $
$0
Form type
4
Filing time
14 Mar 2022, 16:45:47 UTC
Previous filing
28 Jan 2022
Next filing
13 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right to Buy) Award $0 +50,000 $0 50,000 14 Mar 2022 Common Stock 50,000 $31.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.